Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986435 · 5 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| BMS-986435 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Arm A | EXPERIMENTAL | Mild Hepatic Impairment |
| Arm B | EXPERIMENTAL | Moderate Hepatic Impairment |
| Arm C | EXPERIMENTAL | Matched participants with normal hepatic function |
| Treatment A | EXPERIMENTAL | - |
| Treatment B | EXPERIMENTAL | - |
| Treatment C | EXPERIMENTAL | - |
| Treatment D | EXPERIMENTAL | - |
| Treatment E | EXPERIMENTAL | - |
| Treatment F | EXPERIMENTAL | - |
| Treatment G | EXPERIMENTAL | - |
| Treatment H | EXPERIMENTAL | - |
| Treatment I | EXPERIMENTAL | - |
| Treatment J | EXPERIMENTAL | - |
| Treatment K | EXPERIMENTAL | - |
| Treatment L | EXPERIMENTAL | - |
| Treatment A: BMS-986435 Reference Dose 1 | ACTIVE_COMPARATOR | - |
| Treatment B: BMS-986435 Test Dose 1 | EXPERIMENTAL | - |
| Treatment C: BMS-986435 Test Dose 2 | EXPERIMENTAL | - |
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986435 | DRUG | Specified dose on specified days |
| Placebo | OTHER | Specified dose on specified days |
Inclusion Criteria \- Adult participants with stable, symptomatic HFpEF with a normal heart pumping ability. Exclusion Criteria * Participants must not have a known diagnosis of obstructive or genetic hypertrophic cardiomyopathy or infiltrative/storage disorder such as cardiac amyloidosis, or any...
Top 20 of 31 competitors
BMS-986435 is an investigational small molecule being developed by Bristol-Myers Squibb for heart failure, specifically heart failure with preserved ejection fraction (HFpEF). It is also studied in healthy volunteers to assess safety, tolerability, drug levels, and effects. The drug is currently in clinical development and is not approved by the FDA.
BMS-986435 is a small molecule, but its specific molecular target has not been disclosed in available information. The drug is being evaluated for its effects in heart failure with preserved ejection fraction (HFpEF), but the exact mechanism of action is not publicly detailed.
BMS-986435 is developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company is conducting clinical trials to evaluate the drug's safety, tolerability, and efficacy in heart failure and healthy volunteer populations.
BMS-986435 is in Phase 1 clinical development, with one completed Phase 1 study and two active Phase 1 trials. A Phase 2 study in heart failure with preserved ejection fraction (HFpEF) is also active but not recruiting. The drug remains investigational and has not received FDA approval.
BMS-986435 is being studied in several trials, including NCT06122779 (Phase 2 in HFpEF, active not recruiting), NCT06476821 (Phase 1 in healthy Chinese participants, completed), NCT07226817 (Phase 1 bioavailability and food effect study, recruiting), and NCT07248839 (Phase 1 hepatic impairment study, recruiting).
Yes, BMS-986435 is also known as MYK-224. Clinical trial titles refer to the drug as BMS-986435/MYK-224, indicating that both names refer to the same investigational compound being developed by Bristol-Myers Squibb.